PGEN
PGEN clinical trials: PRECIGEN, INC.
Every trial on ClinicalTrials.gov where PRECIGEN, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 6
- As lead sponsor
- 4
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
PGEN on the catalyst calendar · PGEN registry changes
- Primary completion Jan 2029Sponsor estimatePhase 3NCT07901738Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in ChildrenPrecigen, Inc · Recurrent Respiratory Papillomatosis (RRP)Not yet recruitingPGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 11, 2026Sponsor estimatePhase 2NCT06157151PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical CancerPrecigen, Inc · Cervical CancerRecruitingPGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2, 2027Sponsor estimatePhase 4NCT06538480Zopa Retreatment and Vector Shedding in Adults With RRPPrecigen, Inc · Recurrent Respiratory PapillomatosisRecruitingPGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 5, 2024ActualPhase 1/Phase 2NCT04724980Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory PapillomatosisPrecigen, Inc · Recurrent Respiratory PapillomatosisActive, not recruitingPGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 1, 2024ActualPhase 1NCT03927261PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDSPrecigen, Inc · Acute Myeloid LeukemiaActive, not recruitingPGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2024Sponsor estimatePhase 1NCT03907527Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube...Precigen, Inc · Platinum-Resistant Fallopian Tube CarcinomaActive, not recruitingPGENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 18, 2024ActualPhase 1NCT05694364Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor MalignanciesH. Lee Moffitt Cancer Center and Research Institute · Chronic Lymphocytic LeukemiaCompletedPGENCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 23, 2020ActualPhase 1NCT00968760CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid MalignanciesM.D. Anderson Cancer Center · LymphomaCompletedTCRTCollaboratorPGENCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 4, 2020ActualPhase 1NCT03409627Novel INXN-4001 Triple Effector Plasmid in Heart FailureTriple-Gene, LLC · Heart FailureCompletedPGENCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 10, 2019ActualPhase 1NCT03126864Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen...M.D. Anderson Cancer Center · Hematopoietic/Lymphoid CancerTerminatedPGENCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner